Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy
| العنوان: | Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy |
|---|---|
| المؤلفون: | Danuta Gąsior-Perczak, Iwona Pałyga, Magdalena Chrapek, Agnieszka Płusa, Agnieszka Walczyk, Stanisław Góźdź, Aldona Kowalska, Janusz Kopczyński, Kinga Hińcza-Nowak, Artur Kowalik |
| المصدر: | Genes, Vol 12, Iss 1534, p 1534 (2021) Genes Volume 12 Issue 10 |
| بيانات النشر: | MDPI AG, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Male, Drug, B7 Antigens, endocrine system diseases, medicine.drug_class, media_common.quotation_subject, medicine.medical_treatment, QH426-470, Monoclonal antibody, Single Center, Malignancy, medullary thyroid cancer, Article, Immune system, Biomarkers, Tumor, Genetics, medicine, Humans, Thyroid Neoplasms, CD276, Genetics (clinical), Aged, media_common, Aged, 80 and over, business.industry, Computational Biology, Medullary thyroid cancer, Immunotherapy, Middle Aged, medicine.disease, Carcinoma, Neuroendocrine, Tumor Burden, Cancer cell, Cancer research, Female, immunotherapy, business |
| الوصف: | Medullary thyroid cancer (MTC) is a rare malignancy that arises from calcitonin-producing C-cells. Curative treatment for patients with metastatic MTC is challenging. Identifying the mechanisms by which cancer cells inhibit the activity of immune cells provides an opportunity to develop new therapies that restore anticancer activity. Little is known about the immunological phenomena underlying MTC. Here, we examined the expression profile of 395 genes associated with MTC. The study included 51 patients diagnosed with MTC at a single center. Bioinformatical analysis revealed that CD276 expression in MTC cells was at least three-fold higher than that in normal tissue. The expression of CD276 showed a weak but statistically significant positive correlation with tumor diameter, but we did not find a significant association between CD276 expression and other histopathological clinical factors, or the response to initial therapy. A search of published data identified the monoclonal antibody (inhibitor) enoblituzumab as a potential drug for patients diagnosed with MTC overexpressing CD276. |
| وصف الملف: | application/pdf |
| تدمد: | 2073-4425 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0e89ae1c23480b788bb9eb564e96e63Test https://doi.org/10.3390/genes12101534Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b0e89ae1c23480b788bb9eb564e96e63 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20734425 |
|---|